How many drugs treat Myxedema?

Drug Landscape tracks 6 marketed treatments for Myxedema (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/myxedema.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Myxedema — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myxedema (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Myxedema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Synthroid	levothyroxine	Generic (originally multiple — AbbVie/Synthroid)	Thyroid hormone	THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial	2002-08-13
Unithroid	LEVOTHYROXINE SODIUM	Fresenius Kabi	l-Thyroxine	Thyroid hormone receptor beta	2000-01-01
Triostat	LIOTHYRONINE	Pfizer	l-Triiodothyronine	Thyroid hormone receptor alpha	1956-01-01
levothyroxin	levothyroxin	Ain Shams University		THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
Thyroxine	Thyroxine	Cancer Institute and Hospital, Chinese Academy of Medical Sciences		THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial
Triiodothyronine	Triiodothyronine	Northwell Health		THAP domain-containing protein 1, Cytochrome P450 2C9, Proliferating cell nuclear antigen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Ain Shams University · 1 drug in Myxedema
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in Myxedema
Fresenius Kabi · 1 drug in Myxedema
Generic (originally multiple — AbbVie/Synthroid) · 1 drug in Myxedema
Northwell Health · 1 drug in Myxedema
Pfizer · 1 drug in Myxedema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Myxedema:

Cite this brief

Drug Landscape (2026). Myxedema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/myxedema. Accessed 2026-06-10.

Myxedema full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing